Abstract
CYP2C9 is one of the major cytochrome P450 enzymes that play a crucial role in metabolic clearance of several drugs in the current clinical used. CYP2C9 has several allelic variant forms each of which arises from single amino acid substitution and could reduce/increase enzyme activities and affect drug metabolism. Mutant alleles may cause serious toxicity in some narrow therapeutic index drugs. CYP2C9*13, one of the CYP2C9 variant forms that is commonly found in Asian population, has a Leu90Pro amino acid substitution that leads to defective drug metabolism in individuals who carry this allele. It has been reported that metabolic activity of CYP2C9*13 was reduced towards some CYP2C9 substrates compared to wildtype. In this study, X-ray crystal structure of human cytochrome P450 2C9 complexed with flurbiprofen (PDB code: 1R9O) was represented to wildtype and the structure of CYP2C9*13 was constructed based on the X-ray crystal structure of CYP2C9-flurbiprofen complex. Herein, molecular docking of CYP2C9*1 and CYP2C9*13 with flurbiprofen was performed in search for flurbiprofen orientation that corresponds to its binding state before undergoing monooxygenation. Subsequently, molecular dynamics simulation was operated to compare binding of flurbiprofen in catalytic cavity of these 2 variants. Substrate access channel of CYP2C9*13 has a dramatic effect on an interaction between the drug and the enzyme. Consequently, this study can lead to an understanding of structural pathology caused by single amino acid change in CYP2C9*13 variant.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sigel, A., Sigel, H., Sigel, R.K.O.: The Ubiquitous Roles of Cytochrome P450 Proteins. In: Metal Ions in Life Science, vol. 3. John Wiley & Sons Ltd, West Sussex (2007)
Guengerich, F.P.: Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 21, 70–83 (2008)
Anzenbacher, P., Anzenbacherová, E.: Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 58, 737–747 (2001)
Nelson, D.R., Koymans, L., Kamataki, T., Stegeman, J.J., Feyereisen, R., Waxman, D.J., Waterman, M.R., Gotoh, O., Coon, M.J., Estabrook, R.W., Gunsalus, I.C., Nebert, D.W.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1–42 (1996)
Otyepka, M., Skopalik, J., Anzenbacherova, E., Anzenbacher, P.: What common structural features and variations of mammalian P450s are known to date? Biochim. Biophys. Acta. 1770, 376–389 (2007)
Williams, P.A., Cosme, J., Vinkovic, D.M., Ward, A., Angove, H.C., Day, P.J., Vonrhein, C., Tickle, I.J., Jhoti, H.: Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305, 683–686 (2004)
Zhao, Y., Halpert, J.R.: Structure-function analysis of cytochromes P450 2B. Biochem. Biophys. Acta. 1770, 402–412 (2007)
Zhou, S.F., Zhou, Z.W., Huang, M.: Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology (2009), doi: 10.1016/j.tox.2009.08.013
Schwarz, U.I.: Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur. J. Clin. Invest. 33, 23–30 (2003)
Yamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J.A., Guengerich, F.P., Shimada, T.: Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of Warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem. Pharmacol. 56, 243–251 (1998)
Yasar, U., Eliasson, E., Forslund-Bergengren, C., Tybring, G., Gadd, M., Sjoqvist, F., Dahl, M.L.: The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol. 57, 729–735 (2001)
Si, D.Y., Guo, Y.J., Zhang, Y.F., Yang, L., Zhou, H., Zhong, D.F.: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14, 465–469 (2004)
Rosemary, J., Adithan, C.: The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr. Clin. Pharmacol. 2, 93–109 (2007)
Bae, J.W., Kim, H.K., Kim, J.H., Yang, S.I., Kim, M.J., Jang, C.G., Park, Y.S., Lee, S.Y.: Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol. 60, 418–422 (2005)
Guo, Y.J., Wang, Y., Si, D.Y., Fawcett, J.P., Zhong, D.F., Zhou, H.: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 35, 953–961 (2005)
Lee, C.R., Pieper, J.A., Frye, R.F., Hinderliter, A.L., Blaisdell, J.A., Goldstein, J.A.: Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur. J. Clin. Pharmacol. 58(12), 791–794 (2003)
Williams, P.A., Cosme, J., Ward, A., Angova, H.C., Vinkovic, D.M., Jhoti, H.: Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature 424, 464–468 (2003)
Wester, M.R., Yano, J.K., Schoch, G.A., Yang, C., Griffin, K.J., Stout, C.D., Johnson, E.F.: The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0-angstrom resolution. J. Biol. Chem. 279, 35630–35637 (2004)
Zhou, Y.H., Zheng, Q.C., Li, Z.S., Zhang, Y., Sun, M., Sun, C.C., Si, D., Cai, L., Guo, Y., Zhou, H.: On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study. Biochimie 88, 1457–1465 (2006)
Sali, A., Blundell, T.L.: Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993)
Canutescu, A., Shelenkov, A., Dunbrack, R.: A graph-theory algorithm for rapid protein side-chain prediction. Protein Science 12, 2001–2014 (2003)
Huey, R., Morris, G.M., Olson, A.J., Goodsell, D.S.: A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 28, 1145–1152 (2007)
Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., Olson, A.J.: Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639–1662 (1998)
Gotoh, O.: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry 267(1), 83–90 (1992)
Case, D.A., Darden, T.A., Cheatham, T.E., Simmerling, C.L., Wang, J., Duke, R.E., Luo, R., Crowley, M., Walker, R.C., Zhang, W., Merz, K.M., Wang, B., Hayik, S., Roitberg, A., Seabra, G., Kolossváry, I., Wong, K.F., Paesani, F., Vanicek, J., Wu, X., Brozell, S.R., Steinbrecher, T., Gohlke, H., Yang, L., Tan, C., Mongan, J., Hornak, V., Cui, G., Mathews, D.H., Seetin, M.G., Sagui, C., Babin, V., Kollman, P.A.: AMBER 10. University of California, San Francisco (2008)
Miyamoto, S., Kollman, P.A.: SETTLE: An Analytical Version of the SHAKE and RATTLE Algorithms for Rigid Water Models. J. Comp. Chem. 13, 952–962 (1992)
Wolber, G., Langer, T.: LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45, 160–169 (2005)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Saikatikorn, Y., Lertkiatmongkol, P., Assawamakin, A., Ruengjitchatchawalya, M., Tongsima, S. (2010). Study of the Structural Pathology Caused by CYP2C9 Polymorphisms towards Flurbiprofen Metabolism Using Molecular Dynamics Simulation. In: Chan, J.H., Ong, YS., Cho, SB. (eds) Computational Systems-Biology and Bioinformatics. CSBio 2010. Communications in Computer and Information Science, vol 115. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16750-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-16750-8_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-16749-2
Online ISBN: 978-3-642-16750-8
eBook Packages: Computer ScienceComputer Science (R0)